CA9 and cervical cancer: Immunohistochemical methods. Varying extents of mismatch between hypoxia-dependent proteins HIF-1α, CA-IX, and the well-established hypoxia marker drug, pimonidazole, have been reported in human cervical cancer xenografts and human patients with cervix cancer [40,41,42].